Biopharma Daily Stock Updates - 01/26/21

$XBI $154.38 (-1.76%) 📉

COVID:

$MRNA (+3.30%) - Moderna Provides U.S. COVID-19 Vaccine Supply Update

PIPELINE:

$AMRN (-1.06%) - AMARIN EXPANDS CARDIOVASCULAR RISK REDUCTION PATENT INFRINGEMENT LAWSUIT TO INCLUDE HEALTH CARE INSURANCE PROVIDER

$AGIOS (-2.95%) - Agios Announces Phase 3 ACTIVATE-T Trial of Mitapivat Achieved Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Regularly Transfused

$CRDF (+1.55%) - Cardiff Oncology Receives "Study May Proceed" from FDA to Initiate Phase 2 Trial of Onvansertib in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

$AZN (+0.80%) - Symbicort Turbuhaler approved in China as an anti-inflammatory reliever in mild asthma

$ADMA (-0.40%) - ADMA Biologics Receives Unique Permanent J-Code for ASCENIV™

$BCYC (-0.56%) - Bicycle Therapeutics Announces Publication of Article Highlighting Preclinical Data of Tumor-Targeted Immune Cell Agonists (TICAs™) in the Journal for ImmunoTherapy of Cancer

$RYTM (-13.17%) - Rhythm Pharmaceuticals Announces Positive Data with Setmelanotide in Additional MC4R Pathway Deficiency-related Obesities

$MYOV (+9.32%) & $PFE (+0.13%) - Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis

$ELOX (-4.33%) - Eloxx Announces Publication of Scientific Manuscript on ELX-02 in the Journal of Clinical Pharmacology in Drug Development

$AGEN (-5.00%) - Agenus Enters into Clinical Collaboration with Nelum for Zalifrelimab Combination

FINANCIAL:

$CBIO (-7.32%) - Catalyst Biosciences Announces Proposed Public Offering of Common Stock

$PGEN (-8.60%) - Precigen Announces Closing of Public Offering of Common Stock and Full Exercise of Option to Purchase Additional Shares